Loading clinical trials...
Loading clinical trials...
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma
Conditions
Interventions
APX005M
Nivolumab
Locations
23
United States
University of Arizona Cancer Center
Tucson, Arizona, United States
City of Hope
Duarte, California, United States
Yale University
New Haven, Connecticut, United States
Hem-Onc Associates of the Treasure Coast
Port Saint Lucie, Florida, United States
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC)
Baltimore, Maryland, United States
Nebraska Cancer Specialists
Omaha, Nebraska, United States
Start Date
July 10, 2017
Primary Completion Date
November 16, 2020
Completion Date
November 16, 2020
Last Updated
December 26, 2023
NCT04541381
NCT05468034
NCT06204094
NCT05671510
NCT05398783
NCT07446322
Lead Sponsor
Apexigen America, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions